Tumorigenesis is a major hidden danger to human health, with over nine million people worldwide dying from tumors annually. About two-thirds of tumors are caused by persistent infection with oncogenic viruses. Since the human carcinogenic Epstein-Barr virus (EBV) was first discovered, seven human carcinogenic viruses have been identified. Thus, understanding the role of viruses in tumorigenesis is crucial in cancer research. Classical viral infections arise from interactions between viral capsid or envelope proteins and cell surface receptors, which are subsequently internalized through envelope fusion or endocytosis. In this study, we summarize processes by which seven carcinogenic viruses attach to target cells and the co-factors involved.
{"title":"A review: cellular attachment and entry factors of human tumor-associated viruses","authors":"Duo Shi, Yan Zhang, Bin Luo","doi":"10.2217/fvl-2023-0210","DOIUrl":"https://doi.org/10.2217/fvl-2023-0210","url":null,"abstract":"Tumorigenesis is a major hidden danger to human health, with over nine million people worldwide dying from tumors annually. About two-thirds of tumors are caused by persistent infection with oncogenic viruses. Since the human carcinogenic Epstein-Barr virus (EBV) was first discovered, seven human carcinogenic viruses have been identified. Thus, understanding the role of viruses in tumorigenesis is crucial in cancer research. Classical viral infections arise from interactions between viral capsid or envelope proteins and cell surface receptors, which are subsequently internalized through envelope fusion or endocytosis. In this study, we summarize processes by which seven carcinogenic viruses attach to target cells and the co-factors involved.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141050037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: This study aimed to develop a universal vaccine that can effectively address future outbreaks of coronavirus infections. Materials & methods: We developed recombinant DNA vaccines and vaccinia vector vaccines specific for SARS-CoV and SARS-CoV-2 and evaluated them in BALB/c mice. Both cellular and humoral immune responses were analyzed. Results: Compared with those immunized with the SARS-CoV or SARS-CoV-2 vaccine alone, the cross-immune group exhibited a 21.2-fold increase in cellular immune response, an over 80-fold increase in binding antibodies and a 136.7-fold increase in neutralizing antibodies. The combination of recombinant DNA and vaccinia vaccines induced a stronger immune response than DNA vaccine immunization alone. Conclusion: This study demonstrated that cross-immunization with different coronaviruses can induce a broad immune response.
目的：本研究旨在开发一种通用疫苗，以有效应对未来冠状病毒感染的爆发。材料与方法：我们开发了针对 SARS-CoV 和 SARS-CoV-2 的重组 DNA 疫苗和疫苗载体疫苗，并在 BALB/c 小鼠中进行了评估。对细胞和体液免疫反应进行了分析。结果显示与单独免疫 SARS-CoV 或 SARS-CoV-2 疫苗的小鼠相比，交叉免疫组的细胞免疫反应增加了 21.2 倍，结合抗体增加了 80 多倍，中和抗体增加了 136.7 倍。与单独接种 DNA 疫苗相比，联合接种重组 DNA 和疫苗可诱导更强的免疫反应。结论这项研究表明，不同冠状病毒的交叉免疫可诱导广泛的免疫反应。
{"title":"Exploration of the cross-immunity between SARS-CoV and SARS-CoV-2 in mice","authors":"Shuhui Wang, Li Ren, Ying Liu, Xiuli Shen, Yanling Hao, Yiming Shao","doi":"10.2217/fvl-2023-0212","DOIUrl":"https://doi.org/10.2217/fvl-2023-0212","url":null,"abstract":"Aim: This study aimed to develop a universal vaccine that can effectively address future outbreaks of coronavirus infections. Materials & methods: We developed recombinant DNA vaccines and vaccinia vector vaccines specific for SARS-CoV and SARS-CoV-2 and evaluated them in BALB/c mice. Both cellular and humoral immune responses were analyzed. Results: Compared with those immunized with the SARS-CoV or SARS-CoV-2 vaccine alone, the cross-immune group exhibited a 21.2-fold increase in cellular immune response, an over 80-fold increase in binding antibodies and a 136.7-fold increase in neutralizing antibodies. The combination of recombinant DNA and vaccinia vaccines induced a stronger immune response than DNA vaccine immunization alone. Conclusion: This study demonstrated that cross-immunization with different coronaviruses can induce a broad immune response.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140377853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"It's time for a booster: here's your 19th dose of Future Virology!","authors":"Ellen Porter","doi":"10.2217/fvl-2024-0030","DOIUrl":"https://doi.org/10.2217/fvl-2024-0030","url":null,"abstract":"","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140225807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
COVID-19 is a widespread illness that affects human life. Following infection, many patients may suffer long-term sequelae of COVID-19. Forsythiae Fructus is a popular herbal treatment for the common cold and flu. According to studies, the active components in Forsythiae Fructus have potent antiviral properties and can treat various diseases by influencing several pathways. This article explores the mechanism of action and effectiveness of the active components in Forsythiae Fructus for treating COVID-19 through a literature review and network pharmacology techniques, emphasizing their effects on sequelae.
{"title":"Post-COVID-19 symptom burden: treatment with Forsythiae Fructus","authors":"Yan Zhao, Xin Gao, Guangping Wang, Jiali Ren, Weisan Chen, Ying Zhao, Xiankuan Li, Jian Zhang","doi":"10.2217/fvl-2023-0190","DOIUrl":"https://doi.org/10.2217/fvl-2023-0190","url":null,"abstract":"COVID-19 is a widespread illness that affects human life. Following infection, many patients may suffer long-term sequelae of COVID-19. Forsythiae Fructus is a popular herbal treatment for the common cold and flu. According to studies, the active components in Forsythiae Fructus have potent antiviral properties and can treat various diseases by influencing several pathways. This article explores the mechanism of action and effectiveness of the active components in Forsythiae Fructus for treating COVID-19 through a literature review and network pharmacology techniques, emphasizing their effects on sequelae.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140227778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Ohata, Stephen J Kerr, Hay Mar Su Lwin, S. Gatechompol, Siwat Thammapiwan, S. Ubolyam, O. Putcharoen, Jeremy Ross, Raja Iskandar Shah Raja Azwa, Nagalingeswaran Kumarasamy, T. Puthanakit, D. Colby, P. Phanuphak, A. Avihingsanon
The first Bangkok International Symposium on HIV Medicine was launched in January 1998 with the aim to provide up-to-date information on HIV to professional heathcare workers in Thailand and surrounding countries who cannot afford to attend conferences abroad. After several virtual conferences during the COVID-19 pandemic, this is the second face-to-face meeting held in Bangkok from 17 to 19 January 2024. There were a total of six plenary sessions each morning and two afternoon workshops on Wednesday and Thursday. The symposium had expert speakers from Thailand, Australia, Taiwan, India, Malaysia, the UK, the USA, Japan, Singapore, the Philippines and Vietnam.
{"title":"Conference proceedings from the 26th Bangkok International Symposium on HIV Medicine","authors":"P. Ohata, Stephen J Kerr, Hay Mar Su Lwin, S. Gatechompol, Siwat Thammapiwan, S. Ubolyam, O. Putcharoen, Jeremy Ross, Raja Iskandar Shah Raja Azwa, Nagalingeswaran Kumarasamy, T. Puthanakit, D. Colby, P. Phanuphak, A. Avihingsanon","doi":"10.2217/fvl-2024-0016","DOIUrl":"https://doi.org/10.2217/fvl-2024-0016","url":null,"abstract":"The first Bangkok International Symposium on HIV Medicine was launched in January 1998 with the aim to provide up-to-date information on HIV to professional heathcare workers in Thailand and surrounding countries who cannot afford to attend conferences abroad. After several virtual conferences during the COVID-19 pandemic, this is the second face-to-face meeting held in Bangkok from 17 to 19 January 2024. There were a total of six plenary sessions each morning and two afternoon workshops on Wednesday and Thursday. The symposium had expert speakers from Thailand, Australia, Taiwan, India, Malaysia, the UK, the USA, Japan, Singapore, the Philippines and Vietnam.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140232144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alessandro Pennesi, G. Ferrari, Federica Giardina, Sara Piselli, Roberto Lo Savio, Adolfo Carloni, S. Paolucci, F. Baldanti
Aim: To evaluate a label-free and variant-independent assay called direct virus capture (DVC) for detection of intact SARS-CoV-2 virions through light scattering, utilizing an optical inverted laser microscope called nano eye device virus detector (NED-VD). Methods: The DVC assay involves the interaction between ACE2 receptors printed on a glass coverslip substrate, and the S protein on the outer surface of virions. The study was conducted using 191 human swab specimens. Results: In comparison to the RT-PCR assay, the DVC method achieved a sensitivity of 40.5%, specificity of 90.4% and accuracy of 46%. Conclusion: The study presents a promising qualitative pre-screening test to evaluate the presence of whole virions and reduce the number of PCR tests.
{"title":"Direct virus capture assay for label-free detection of SARS-CoV-2 virions using laser microscopy","authors":"Alessandro Pennesi, G. Ferrari, Federica Giardina, Sara Piselli, Roberto Lo Savio, Adolfo Carloni, S. Paolucci, F. Baldanti","doi":"10.2139/ssrn.4494421","DOIUrl":"https://doi.org/10.2139/ssrn.4494421","url":null,"abstract":"Aim: To evaluate a label-free and variant-independent assay called direct virus capture (DVC) for detection of intact SARS-CoV-2 virions through light scattering, utilizing an optical inverted laser microscope called nano eye device virus detector (NED-VD). Methods: The DVC assay involves the interaction between ACE2 receptors printed on a glass coverslip substrate, and the S protein on the outer surface of virions. The study was conducted using 191 human swab specimens. Results: In comparison to the RT-PCR assay, the DVC method achieved a sensitivity of 40.5%, specificity of 90.4% and accuracy of 46%. Conclusion: The study presents a promising qualitative pre-screening test to evaluate the presence of whole virions and reduce the number of PCR tests.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140233378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: To retrospectively assess the efficacy and safety of sofosbuvir/velpatasvir for hepatitis C virus (HCV) genotype 3b in HIV-infected patients receiving antiretroviral therapy (ART) treatment of lamivudine/tenofovir disoproxil fumarate/efavirenz. Methods: The primary end point of HCV treatment was estimated by sustained virologic response 12 weeks after treatment (SVR12). Results: Sixteen subjects who were followed up for 48 weeks after treatment were included. The SVR12 and SVR48 were 87.5% (95% CI: 60.4–97.8%) and 81.3% (95% CI: 53.7–95.0%), respectively. One patient experienced persistent low-level viremia of HIV after 12 weeks of treatment. Conclusion: Twelve weeks of SOF/VEL is safe but has limited efficacy for HCV GT3b in HIV-infected patients receiving ART regimen including efavirenz, especially among patients with baseline HCV RNA≥6.0 log10 IU/ml.
{"title":"Decreased efficacy of sofosbuvir/velpatasvir in HIV patients coinfected with HCV genotype 3b","authors":"Jingdi Zhou, Fada Wang, Lanzhi Li, Jing-Yu Li, En-Qiang Chen","doi":"10.2217/fvl-2023-0112","DOIUrl":"https://doi.org/10.2217/fvl-2023-0112","url":null,"abstract":"Aim: To retrospectively assess the efficacy and safety of sofosbuvir/velpatasvir for hepatitis C virus (HCV) genotype 3b in HIV-infected patients receiving antiretroviral therapy (ART) treatment of lamivudine/tenofovir disoproxil fumarate/efavirenz. Methods: The primary end point of HCV treatment was estimated by sustained virologic response 12 weeks after treatment (SVR12). Results: Sixteen subjects who were followed up for 48 weeks after treatment were included. The SVR12 and SVR48 were 87.5% (95% CI: 60.4–97.8%) and 81.3% (95% CI: 53.7–95.0%), respectively. One patient experienced persistent low-level viremia of HIV after 12 weeks of treatment. Conclusion: Twelve weeks of SOF/VEL is safe but has limited efficacy for HCV GT3b in HIV-infected patients receiving ART regimen including efavirenz, especially among patients with baseline HCV RNA≥6.0 log10 IU/ml.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140419257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oppah Kuguyo, Racheal S Dube Mandishora, N. Soko, Takudzwa Magwaku, A. Matimba, C. Dandara
Aim: Investigate the role of host genetic variations in high-risk human papillomaviruses (HR-HPVs). Methods: This cross-sectional study recruited 238 cervical cancer patients. Variants in transport (ABCC2), xenobiotic metabolism ( GSTP, GSTT1, GSTM1, NQO1), DNA repair ( ERCC1, XRCC1), immune response ( TLR4) and apoptosis ( CASP8, FASL, p53) genes were characterized. Tumor DNA was genotyped for 14 HR-HPVs. Results: GSTP rs1695GG, XRCC1 rs1799782TT and GSTT1 del/del were associated with HPV51 (odds ratio [OR]: 3.9; 95% confidence interval [CI]: 1.3–11.7; p = 0.02) and HPV58 (OR: 2.4; 95% CI: 1.2–5.8; p = 0.048), respectively. CASP8 rs3834129del/del was associated with HPV16/18 (OR: 2.7; 95% CI: 1.2–6.0; p = 0.017) and HPV monoinfections (OR: 2.3; 95% CI: 1.2–4.4; p = 0.008). Conclusion: GSTP, GSTT1, XRCC1 and CASP8 variants were associated with HPV-positivity. With further research, a genetic-based screening tool can be developed, to use with HPV vaccines toward preventing cervical cancer.
{"title":"GSTP, GSTT1, XRCC1 and CASP8 genetic variations are associated with human papillomavirus in women with cervical cancer from Zimbabwe","authors":"Oppah Kuguyo, Racheal S Dube Mandishora, N. Soko, Takudzwa Magwaku, A. Matimba, C. Dandara","doi":"10.2217/fvl-2023-0154","DOIUrl":"https://doi.org/10.2217/fvl-2023-0154","url":null,"abstract":"Aim: Investigate the role of host genetic variations in high-risk human papillomaviruses (HR-HPVs). Methods: This cross-sectional study recruited 238 cervical cancer patients. Variants in transport (ABCC2), xenobiotic metabolism ( GSTP, GSTT1, GSTM1, NQO1), DNA repair ( ERCC1, XRCC1), immune response ( TLR4) and apoptosis ( CASP8, FASL, p53) genes were characterized. Tumor DNA was genotyped for 14 HR-HPVs. Results: GSTP rs1695GG, XRCC1 rs1799782TT and GSTT1 del/del were associated with HPV51 (odds ratio [OR]: 3.9; 95% confidence interval [CI]: 1.3–11.7; p = 0.02) and HPV58 (OR: 2.4; 95% CI: 1.2–5.8; p = 0.048), respectively. CASP8 rs3834129del/del was associated with HPV16/18 (OR: 2.7; 95% CI: 1.2–6.0; p = 0.017) and HPV monoinfections (OR: 2.3; 95% CI: 1.2–4.4; p = 0.008). Conclusion: GSTP, GSTT1, XRCC1 and CASP8 variants were associated with HPV-positivity. With further research, a genetic-based screening tool can be developed, to use with HPV vaccines toward preventing cervical cancer.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140429130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Roberta Monardo, A. Mastrangelo, Laura Galli, A. Tomelleri, V. Spagnuolo, C. Oltolini, Giacomo Ponta, C. Campochiaro, G. Cavalli, L. Dagna, F. Ciceri, Paola Cinque, P. Scarpellini, Antonella Castagna, M. Ripa
Aim: Aim of this study was to evaluate the effect of anakinra (ANK) addition to remdesivir (RDV) on all-cause 28-day mortality in patients hospitalized with COVID-19. Patients & methods: ANK was administered intravenously at a dose of 5 mg/kg every 12 h in patients with severe respiratory failure and pronounced inflammatory status. 58 patients were treated with RDV + ANK, 219 patients with RDV. Results: The estimate of mortality at 28 days was 17.2% in the RDV + ANK group and 21.4% in the RDV group. Median time to death was 14 days in the RDV + ANK group and 19 in the RDV group. Conclusion: Despite severe respiratory failure and pronounced inflammatory status, patients who received RDV + ANK had similar mortality compared with patients who received RDV.
{"title":"Real-life use of high-dose anakinra in patients with COVID-19 treated with remdesivir","authors":"Roberta Monardo, A. Mastrangelo, Laura Galli, A. Tomelleri, V. Spagnuolo, C. Oltolini, Giacomo Ponta, C. Campochiaro, G. Cavalli, L. Dagna, F. Ciceri, Paola Cinque, P. Scarpellini, Antonella Castagna, M. Ripa","doi":"10.2217/fvl-2023-0132","DOIUrl":"https://doi.org/10.2217/fvl-2023-0132","url":null,"abstract":"Aim: Aim of this study was to evaluate the effect of anakinra (ANK) addition to remdesivir (RDV) on all-cause 28-day mortality in patients hospitalized with COVID-19. Patients & methods: ANK was administered intravenously at a dose of 5 mg/kg every 12 h in patients with severe respiratory failure and pronounced inflammatory status. 58 patients were treated with RDV + ANK, 219 patients with RDV. Results: The estimate of mortality at 28 days was 17.2% in the RDV + ANK group and 21.4% in the RDV group. Median time to death was 14 days in the RDV + ANK group and 19 in the RDV group. Conclusion: Despite severe respiratory failure and pronounced inflammatory status, patients who received RDV + ANK had similar mortality compared with patients who received RDV.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2024-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140430481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anwar Ahmed, A. Alhetheel, Shama Parveen, F. Almajhdi, Noorah A. Alkubaisi, Muslim Mohammed Al-Saadi
Aim: The study aimed to analyze human respiratory syncytial virus (hRSV) strains in nasopharyngeal aspirates obtained retrospectively. Materials & methods: Clinical information of ARI patients (n = 53) was accessed and 2nd hypervariable region of G protein gene of RSV was sequenced and analyzed. Results: Cough (98.1%), fever 40 (75.4%) and shortness of breath 32 (60.3%) were the common symptom. Sequence determination (n = 45) categorized all the strains in ON1 genotype. Potential O- and N- glycosylation were observed at some sites and purifying selections were observed at 274 and 320 codon positions. Conclusion: The study reports replacement of other RSVA genotypes with ON1. The future course of studies should emphasize on clinical implications of presence of hRSVA-ON1 genotype in a given population.
{"title":"Human RSVA-ON1, the only genotype present during 2019–2020 winter season in Riyadh, Saudi Arabia: a retrospective study","authors":"Anwar Ahmed, A. Alhetheel, Shama Parveen, F. Almajhdi, Noorah A. Alkubaisi, Muslim Mohammed Al-Saadi","doi":"10.2217/fvl-2023-0173","DOIUrl":"https://doi.org/10.2217/fvl-2023-0173","url":null,"abstract":"Aim: The study aimed to analyze human respiratory syncytial virus (hRSV) strains in nasopharyngeal aspirates obtained retrospectively. Materials & methods: Clinical information of ARI patients (n = 53) was accessed and 2nd hypervariable region of G protein gene of RSV was sequenced and analyzed. Results: Cough (98.1%), fever 40 (75.4%) and shortness of breath 32 (60.3%) were the common symptom. Sequence determination (n = 45) categorized all the strains in ON1 genotype. Potential O- and N- glycosylation were observed at some sites and purifying selections were observed at 274 and 320 codon positions. Conclusion: The study reports replacement of other RSVA genotypes with ON1. The future course of studies should emphasize on clinical implications of presence of hRSVA-ON1 genotype in a given population.","PeriodicalId":12505,"journal":{"name":"Future Virology","volume":null,"pages":null},"PeriodicalIF":3.1,"publicationDate":"2023-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138959903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：